Detalles de la búsqueda
1.
Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia.
Mol Cancer
; 22(1): 177, 2023 11 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37932786
2.
Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia.
Leuk Res
; 112: 106754, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34906861
3.
Reciprocal interactions among Cobll1, PACSIN2, and SH3BP1 regulate drug resistance in chronic myeloid leukemia.
Cancer Med
; 11(21): 4005-4020, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35352878
4.
Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia.
Int J Hematol
; 111(3): 417-426, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31863342
5.
Compound mutations involving T315I and P-loop mutations are the major components of multiple mutations detected in tyrosine kinase inhibitor resistant chronic myeloid leukemia.
Leuk Res
; 76: 87-93, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30503643
6.
Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy.
Leuk Lymphoma
; 59(1): 105-113, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28540759
7.
BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors.
Cancer Med
; 7(10): 5107-5117, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30171671
Resultados
1 -
7
de 7
1
Próxima >
>>